Early Data Suggests a Trend Toward Improvement in Pain Efficacy UTOPIA-1 is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer- related pain. SASKATOON, SK, Jan. 8, 2026 /PRNewswire/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug c ...

PALO ALTO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced confirmed Dream Bowl 2026 Meme Coins claim process on December 24, 2025. Powered by Datavault AI’s patented, encrypted blockchain infrastructure and real-wor ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on December 19, 2025 Registration No. 333-290995 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Semnur Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 98-1659463 (Primary Standard Industrial Classification Code Number) Pa ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Scilex Holding Company 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) Henry Ji, Ph.D. Chief Executive Officer, President & Chairperson 960 San Antonio Road Palo Alto, CA 94303 (650) 516-4310 (Na ...

Core Insights - Cumberland Pharmaceuticals has announced that its Caldolor (ibuprofen) Injection is now associated with a permanent J-code (J1741) and a reimbursement price, providing a CMS-covered non-opioid option for pain and fever management [1][2][5] Group 1: Product Update - Caldolor is now linked to an established reimbursement price, allowing healthcare providers to access a reimbursable non-opioid alternative for pain management [3] - The product is indicated for managing mild to moderate pain and as an adjunct for moderate to severe pain, as well as for fever reduction [4] Group 2: Industry Context - The introduction of Caldolor as a non-opioid alternative is significant in the context of the ongoing opioid crisis, supporting safer pain management strategies [2] - The update aligns with opioid-sparing initiatives, helping healthcare providers make clinically appropriate decisions [3] Group 3: Company Overview - Cumberland Pharmaceuticals is the largest biopharmaceutical company based in Tennessee, focusing on unique products that enhance patient care [5] - The company’s portfolio includes several FDA-approved products, with Caldolor being a key offering [6]

Core Viewpoint - Scilex Holding Company has successfully closed the exercise of existing warrants, generating approximately $20.3 million in gross proceeds, which will be used for working capital and general corporate purposes [1][4]. Group 1: Warrants and Proceeds - The company exercised two sets of existing warrants, totaling 904,396 shares, at a reduced exercise price of $22.51 per share [1]. - The April 2024 Warrants were originally priced at $38.50 per share, while the December 2024 Warrants had an exercise price of $22.72 per share [1]. - The gross proceeds from the exercise of these warrants were approximately $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company issued a new unregistered warrant for 1,356,594 shares at an exercise price of $29.00 per share, which is exercisable immediately and has a five-year term [3]. - The new warrant was offered in a private placement under Section 4(a)(2) of the Securities Act and Regulation D [5]. Group 3: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [9][10]. - Scilex has three product candidates in development, including SP-102, SP-103, and SP-104, which are aimed at various pain management indications [10].

Core Viewpoint - Scilex Holding Company has entered into a definitive agreement to exercise existing warrants, which is expected to generate approximately $20.3 million in gross proceeds for the company [1][4]. Group 1: Existing Warrants - The company will exercise a total of 428,572 shares from April 2024 Warrants at an exercise price of $38.50 per share and 475,824 shares from December 2024 Warrants at an exercise price of $22.72 per share [1]. - The aggregate gross proceeds from the exercise of these existing warrants are anticipated to be around $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company will issue a new unregistered warrant to purchase up to 1,356,594 shares of common stock at an exercise price of $29.00 per share [3]. - The new warrant will be exercisable immediately upon issuance and will have a term of five years [3]. Group 3: Use of Proceeds - The net proceeds from the offering are expected to be utilized for working capital and general corporate purposes [4]. Group 4: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [7][8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [8][9].

Core Viewpoint - Scilex Holding Company is involved in a voluntary distribution of Dream Bowl 2026 Meme Coins to its common stockholders, facilitated by Datavault AI Inc, as a gesture of appreciation for their relationship [1][2] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products aimed at treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][4] - The company has commercial products including ZTlido, ELYXYB, and Gloperba, targeting high unmet medical needs in pain management [4][5] Product Pipeline - Scilex has three product candidates in development: - SP-102, a viscous gel for epidural injections to treat lumbosacral radicular pain, which has completed a Phase 3 study and received Fast Track status from the FDA [5] - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial and also received Fast Track status [6] - SP-104, a low-dose naltrexone hydrochloride capsule for fibromyalgia treatment [6] Distribution Details - The distribution of Dream Bowl 2026 Meme Coins will occur on November 25, 2025, for record holders of Scilex common stock, with further instructions to be provided by Datavault AI [1][2] - The payment date for the distribution is subject to the Board of Directors of Datavault AI and may change prior to the actual payment date [2][3]

Core Insights - Scilex Holding Company is sponsoring the Dream Bowl 2026 and will distribute a unique digital collectible, the Dream Bowl 2026 Meme Coin, to its shareholders [1][2] - Shareholders as of November 14, 2025, will receive one meme coin for each common share held, with airdrops occurring on or after November 25, 2025 [2] - The Dream Bowl event will take place on January 11, 2026, at AT&T Stadium in Dallas, Texas, featuring elite athletes and e-sports competitions [3] Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][4] - The company has commercial products including ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [4][5] - Scilex is developing three product candidates: SP-102 for lumbosacral radicular pain, SP-103 for acute pain, and SP-104 for fibromyalgia [5][6] Datavault AI Partnership - Datavault AI is involved in the distribution of the meme coin and offers a cloud-based platform for data experiences and monetization [7] - The partnership aims to enhance the recognition of ownership and provide utility through ticketing and event insights for the Dream Bowl [2][3]

Table of Contents As filed with the U.S. Securities and Exchange Commission on October 21, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Semnur Pharmaceuticals, Inc. (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies to: Jeffrey T. Hartlin, Esq. Elizabeth A. Razzano, Esq. (Exact name of registrant as specified in its charter) Paul Hast ...